# Cost-effectiveness of national cervical screen-and-treat policies in Uganda

Source: https://onco.cc/key-papers/paper-rukundo-ayeh-via-screen-treat-uganda-bmjph-2026/  
OnCo record `paper-rukundo-ayeh-via-screen-treat-uganda-bmjph-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A microsimulation of 30 visual-inspection screen-and-treat policies for Ugandan women aged 25 to 49 found that 13% to 50% of cervical cancer deaths could be averted, at 88 to 313 US dollars per quality-adjusted life year, and that treating women who screen positive matters as much as screening more.

## Summary

Published as "Optimising a national screen-and-treat cervical cancer strategy in Uganda: a microsimulation cost-effectiveness and budget impact analysis". The authors note that fewer than a third of Ugandan women have ever been screened and that current guidelines recommend screening women aged 25 to 49 every three years, and they model policies varying screening frequency, uptake and treatment follow-through over 15 years.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: BMJ Public Health
- Year: 2026
- DOI: 10.1136/bmjph-2026-005684
- Authors: Rukundo-Ayeh T, McBain RK, Rasmussen PW, Nakisige C, Beyeza-Kashesya J, Wanyenze RK, Mutungi G, Bogart LM, Wagner GJ
- Findings: Depending on frequency, uptake and treatment follow-through, 13% to 50% of deaths could be averted compared with current levels.; Fifteen-year costs ranged from 32.9 to 158.6 million US dollars, 5 to 23 dollars per eligible woman.; Incremental cost-effectiveness ratios ranged from 88 to 313 US dollars per quality-adjusted life year gained.; Policies with lower treatment follow-through were dominated by those with higher follow-through, regardless of screening uptake.
- What it means: For Uganda's screening programme, making sure women who test positive are treated is a better use of money than screening more women without that follow-through.
- Caveats: A model of visual inspection screening; HPV testing was not among the 30 policies.; Costs and effects depend on the model's assumptions.

## Sources

- BMJ Public Health 2026: https://doi.org/10.1136/bmjph-2026-005684
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42968783/

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- institutions: [Ministry of Health, Uganda](https://onco.cc/institutions/uganda-ministry-of-health/)

---
JSON: https://onco.cc/api/v1/entities/paper-rukundo-ayeh-via-screen-treat-uganda-bmjph-2026.json